Sign In
Buy PGEN
$6.27
+0.330 (+5.56%)
At Close: Jul 31, 2026
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
07:25pm, Wednesday, 19'th Mar 2025
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.09 per share a year ago.
Precigen Reports Full Year 2024 Financial Results and Business Updates
04:05pm, Wednesday, 19'th Mar 2025
FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025 Results from pivot
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
08:05am, Thursday, 13'th Mar 2025
GERMANTOWN, Md. , March 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement
08:56am, Friday, 28'th Feb 2025
BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge be
– Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, would provide significant improvements in the treatment, diagnosis or prevention of serio
Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy?
10:55am, Thursday, 20'th Feb 2025
Precigen, Inc. (PGEN) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PGEN's 50-day simple moving average crossed above its 2
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 13'th Jan 2025
– PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease – – Company completed BLA submission for PRGN-2012 for treat
Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:30am, Thursday, 09'th Jan 2025
GERMANTOWN, Md. , Jan. 9, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
02:34pm, Thursday, 02'nd Jan 2025
The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.
– PRGN-2012 has the potential to be the first FDA-approved therapeutic for the treatment of adults with RRP, a rare and devastating chronic disease for which the current standard-of-care is repe
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock
09:00am, Friday, 27'th Dec 2024
GERMANTOWN, Md. , Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of
Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates
06:45pm, Thursday, 14'th Nov 2024
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.08 per share a year ago.
Precigen Reports Third Quarter 2024 Financial Results and Business Updates
04:30pm, Thursday, 14'th Nov 2024
– Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012 † in RRP under acceler
Precigen to Participate in the Stifel 2024 Healthcare Conference
04:05pm, Tuesday, 12'th Nov 2024
GERMANTOWN, Md. , Nov. 12, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives
Precigen to Participate in the 2024 Cantor Global Healthcare Conference
04:30pm, Monday, 16'th Sep 2024
GERMANTOWN, Md. , Sept. 16, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o
